Genomma Lab Internacional. de Toekomstige groei

Future criteriumcontroles 5/6

Genomma Lab Internacional. de zal naar verwachting groeien in winst en omzet met respectievelijk 20% en 9.9% per jaar. De winst per aandeel zal naar verwachting groeien met 19% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 22.2% zijn.

Belangrijke informatie

20.0%

Groei van de winst

19.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	19.6%
Inkomstengroei	9.9%
Toekomstig rendement op eigen vermogen	22.2%
Dekking van analisten	Low
Laatst bijgewerkt	30 Oct 2024

Recente toekomstige groei-updates

Recent updates

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Oct 17

Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)

Sep 11

With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For

Jul 12

These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

May 31

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Jan 29

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?

Nov 07

Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?

Mar 31

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?

Feb 24

Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?

Dec 07

Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic

Sep 24

Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts

Aug 01

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Jul 27

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Mar 22

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?

Feb 15

Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly

Nov 24

Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock

Sep 08

Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price

Jun 10

Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?

May 24

Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?

May 06

Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%

Mar 13

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Feb 19

Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?

Feb 02

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?

Jan 15

What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?

Dec 28

Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain

Dec 10

Winst- en omzetgroeiprognoses

BMV:LAB B - Toekomstschattingen van analisten en financiële gegevens uit het verleden (MXN Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	21,112	2,771	2,078	N/A	4
12/31/2025	19,617	2,397	2,277	N/A	5
12/31/2024	18,271	2,172	1,667	N/A	2
9/30/2024	17,466	1,603	2,254	2,569	N/A
6/30/2024	16,767	1,313	1,443	1,767	N/A
3/31/2024	16,486	1,045	1,741	1,810	N/A
12/31/2023	16,467	1,085	1,920	2,247	N/A
9/30/2023	17,074	1,392	1,436	1,775	N/A
6/30/2023	17,030	1,421	1,133	1,519	N/A
3/31/2023	16,983	1,408	934	1,347	N/A
12/31/2022	16,820	1,389	1,632	2,055	N/A
9/30/2022	16,778	1,359	1,821	2,409	N/A
6/30/2022	16,412	1,353	1,895	2,559	N/A
3/31/2022	15,954	1,328	1,593	2,327	N/A
12/31/2021	15,487	1,308	632	1,468	N/A
9/30/2021	14,868	1,352	778	1,495	N/A
6/30/2021	14,312	1,368	572	1,283	N/A
3/31/2021	14,083	1,416	580	1,316	N/A
12/31/2020	13,870	1,404	1,010	1,715	N/A
9/30/2020	13,619	1,179	404	1,268	N/A
6/30/2020	13,268	1,003	522	1,337	N/A
3/31/2020	12,910	886	494	1,277	N/A
12/31/2019	12,713	750	130	1,007	N/A
9/30/2019	12,617	935	66	1,319	N/A
6/30/2019	12,274	925	-335	1,229	N/A
3/31/2019	11,921	986	-87	1,551	N/A
12/31/2018	11,794	1,109	50	1,562	N/A
9/30/2018	11,556	1,242	418	1,352	N/A
6/30/2018	11,900	1,249	N/A	1,214	N/A
3/31/2018	11,886	1,218	N/A	1,189	N/A
12/31/2017	12,078	1,279	N/A	1,392	N/A
9/30/2017	11,898	958	N/A	1,293	N/A
6/30/2017	11,741	1,212	N/A	1,326	N/A
3/31/2017	11,669	-1,603	N/A	1,459	N/A
12/31/2016	11,316	-1,681	N/A	1,543	N/A
9/30/2016	11,287	-3,447	N/A	1,388	N/A
6/30/2016	10,988	-3,759	N/A	1,571	N/A
3/31/2016	11,125	-895	N/A	587	N/A
12/31/2015	11,042	-1,137	N/A	1,188	N/A
9/30/2015	11,211	1,109	N/A	1,577	N/A
6/30/2015	11,946	1,410	N/A	1,600	N/A
3/31/2015	11,871	1,396	N/A	1,338	N/A
12/31/2014	11,541	1,432	N/A	1,039	N/A
9/30/2014	12,375	1,776	N/A	1,081	N/A
6/30/2014	12,082	1,766	N/A	1,230	N/A
3/31/2014	11,715	1,775	N/A	1,898	N/A
12/31/2013	11,361	1,752	N/A	1,871	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei LAB B ( 20% per jaar) ligt boven de spaarquote ( 8.1% ).

Winst versus markt: De winst van LAB B ( 20% per jaar) zal naar verwachting sneller groeien dan de MX markt ( 11.3% per jaar).

Hoge groeiwinsten: De winst van LAB B zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van LAB B ( 9.9% per jaar) zal naar verwachting sneller groeien dan de markt MX ( 7.1% per jaar).

Hoge groei-inkomsten: De omzet van LAB B ( 9.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen LAB B zal naar verwachting over 3 jaar hoog zijn ( 22.2 %)

Genomma Lab Internacional. de Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 19%

Price target increased by 9.1% to Mex$26.00

Consensus EPS estimates increase by 18%

Price target increased by 9.9% to Mex$21.43

Price target decreased by 8.4% to Mex$20.03

Consensus EPS estimates fall by 21%

Recent updates

Now 21% undervalued

Consensus EPS estimates increase by 19%

Price target increased by 9.1% to Mex$26.00

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024

Genomma Lab Pharma Manufacturing Facility Receives Pending GMP Certification for the Mexican Market from the Mexican Ministry of Health's Federal Committee

Consensus EPS estimates increase by 18%

Price target increased by 9.9% to Mex$21.43

Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For

Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024

Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend

Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend

These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

Price target decreased by 8.4% to Mex$20.03

First quarter 2024 earnings: Revenues exceed analyst expectations

Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 24, 2024

Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend

Full year 2023 earnings released: EPS: Mex$1.08 (vs Mex$1.40 in FY 2022)

Consensus EPS estimates fall by 21%

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 21, 2024

Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?

Third quarter 2023 earnings released: EPS: Mex$0.39 (vs Mex$0.40 in 3Q 2022)

Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: Mex$0.43 (vs Mex$0.40 in 2Q 2022)

Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023

First quarter 2023 earnings released

Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 7.4% to Mex$22.78

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?

Full year 2022 earnings released: EPS: Mex$1.40 (vs Mex$1.30 in FY 2021)

Now 22% undervalued

Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 22, 2023

Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?

Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes

Insufficient new directors

Upcoming dividend of Mex$0.38 per share

Third quarter 2022 earnings released: EPS: Mex$0.40 (vs Mex$0.39 in 3Q 2021)

Genomma Lab Internacional, S.A.B. De C.V. Cash Dividend

Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2022 Results on Oct 26, 2022

Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic

Consensus revenue estimates increase by 22%

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 15%

Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2022 Results on Jul 27, 2022

Genomma Lab Internacional, S.A.B. de C.V. Declares Second Cash Dividend Payment

Consensus EPS estimates fall by 15%

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2022 Results on Apr 27, 2022

Consensus EPS estimates increase by 14%

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?

Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2021 Results on Feb 23, 2022

Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly

Third quarter 2021 earnings released: EPS Mex$0.39 (vs Mex$0.40 in 3Q 2020)

Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock

Second quarter 2021 earnings released: EPS Mex$0.38 (vs Mex$0.36 in 2Q 2020)

Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price